NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-12

AUTHORS

S. F. Dent, K. A. Gelmon, K. N. Chi, D. J. Jonker, N. Wainman, C. A. Capier, E. X. Chen, J. F. Lyons, L. Seymour

ABSTRACT

PURPOSE: AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and pharmacodynamic properties of AT9283. PATIENTS AND METHODS: Patients with advanced, incurable solid tumors or non-Hodgkin's lymphoma received AT9283 as a continuous 24-hour infusion on days 1, 8 of a 21-day cycle. A 3 + 3 dose escalation design was used with a starting dose of 1.5 mg/m(2)/day. Pharmacokinetic samples were collected from all patients on cycle one, and pharmacodynamic samples were collected from 4 patients at the recommended phase II dose (RP2D). RESULTS: 35 patients were evaluable for toxicity and 32 were evaluable for response. AT9283 was well tolerated, with main toxicities being reversible dose-related fatigue, gastrointestinal disturbance, anemia, lymphocytopenia and neutropenia. The dose limiting toxicities were febrile neutropenia (two patients) and neutropenia with grade 3 infection (1 patient) at 47 mg/m(2)/day (established as the maximum tolerated dose). The RP2D was 40 mg/m(2)/day. Pharmacokinetic analyses showed AT9283 appeared to follow linear kinetics, with a mean elimination half-life of 8.2 h. Pharmacodynamic analyses showed no consistent or significant changes, but trends suggested evidence of AT9283 inhibition and anti-proliferative activity. One patient had partial response and four patients experienced RECIST stable disease (median 2.6 months). CONCLUSION: In this study, AT9283 was well tolerated. The RP2D is 40 mg/m(2)/day on days 1, 8 of a 21-day cycle. Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers. More... »

PAGES

1522-1529

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9

DOI

http://dx.doi.org/10.1007/s10637-013-0018-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1030261706

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24072436


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzimidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Histones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ki-67 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proliferating Cell Nuclear Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Protein p53", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urea", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, 501 Smyth Rd, K1H 8L6, Ottawa, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dent", 
        "givenName": "S. F.", 
        "id": "sg:person.01005512156.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005512156.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "Division of Medical Oncology, BC Cancer Agency - Vancouver Cancer Centre, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gelmon", 
        "givenName": "K. A.", 
        "id": "sg:person.01173252503.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "Division of Medical Oncology, BC Cancer Agency - Vancouver Cancer Centre, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "K. N.", 
        "id": "sg:person.01142252161.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, 501 Smyth Rd, K1H 8L6, Ottawa, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jonker", 
        "givenName": "D. J.", 
        "id": "sg:person.0602472015.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602472015.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "NCIC Clinical Trials Group, Cancer Research Institute, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wainman", 
        "givenName": "N.", 
        "id": "sg:person.0725434730.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725434730.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "BC Cancer Agency - Vancouver Cancer Centre, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Capier", 
        "givenName": "C. A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Princess Margaret Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.415224.4", 
          "name": [
            "University Health Network-Princess Margaret Hospital, Oncology, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "E. X.", 
        "id": "sg:person.0754450325.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754450325.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Astex Pharmaceuticals, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lyons", 
        "givenName": "J. F.", 
        "id": "sg:person.01133244421.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133244421.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University", 
          "id": "https://www.grid.ac/institutes/grid.410356.5", 
          "name": [
            "NCIC Clinical Trials Group, Cancer Research Institute, Kingston, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seymour", 
        "givenName": "L.", 
        "id": "sg:person.01327242410.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327242410.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-010-1377-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003176121", 
          "https://doi.org/10.1007/s00280-010-1377-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0962-8924(00)01880-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005800453"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/91.13.1160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006611610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2010.15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007310794", 
          "https://doi.org/10.1038/leu.2010.15"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/path.1711690415", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009072534"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/94.17.1320", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009989679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-0431", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011939272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-5268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016270721"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-10-0299", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020215440"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/emboj/17.11.3052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022175488"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.1200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031753113"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.26324", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035093358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2006-07-037671", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035758193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.12148", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036865215"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1054/bjoc.2000.1684", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037558742", 
          "https://doi.org/10.1054/bjoc.2000.1684"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdr451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041877696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrm1245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049953107", 
          "https://doi.org/10.1038/nrm1245"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrm1245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049953107", 
          "https://doi.org/10.1038/nrm1245"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35048096", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051541099", 
          "https://doi.org/10.1038/35048096"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35048096", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051541099", 
          "https://doi.org/10.1038/35048096"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm800984v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055955939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm800984v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055955939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cc.8.12.8741", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072300058"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075250639", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075266210", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077018133", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.2519", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079371368"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-12", 
    "datePublishedReg": "2013-12-01", 
    "description": "PURPOSE: AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and pharmacodynamic properties of AT9283.\nPATIENTS AND METHODS: Patients with advanced, incurable solid tumors or non-Hodgkin's lymphoma received AT9283 as a continuous 24-hour infusion on days 1, 8 of a 21-day cycle. A 3 + 3 dose escalation design was used with a starting dose of 1.5 mg/m(2)/day. Pharmacokinetic samples were collected from all patients on cycle one, and pharmacodynamic samples were collected from 4 patients at the recommended phase II dose (RP2D).\nRESULTS: 35 patients were evaluable for toxicity and 32 were evaluable for response. AT9283 was well tolerated, with main toxicities being reversible dose-related fatigue, gastrointestinal disturbance, anemia, lymphocytopenia and neutropenia. The dose limiting toxicities were febrile neutropenia (two patients) and neutropenia with grade 3 infection (1 patient) at 47 mg/m(2)/day (established as the maximum tolerated dose). The RP2D was 40 mg/m(2)/day. Pharmacokinetic analyses showed AT9283 appeared to follow linear kinetics, with a mean elimination half-life of 8.2 h. Pharmacodynamic analyses showed no consistent or significant changes, but trends suggested evidence of AT9283 inhibition and anti-proliferative activity. One patient had partial response and four patients experienced RECIST stable disease (median 2.6 months).\nCONCLUSION: In this study, AT9283 was well tolerated. The RP2D is 40 mg/m(2)/day on days 1, 8 of a 21-day cycle. Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-013-0018-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "name": "NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies", 
    "pagination": "1522-1529", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9029856cbb059630e633c78f2e4fc60afab3851146d17aa78dc1cb765afd2c47"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24072436"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-013-0018-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1030261706"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-013-0018-9", 
      "https://app.dimensions.ai/details/publication/pub.1030261706"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-013-0018-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9'


 

This table displays all metadata directly associated to this object as RDF triples.

290 TRIPLES      21 PREDICATES      73 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-013-0018-9 schema:about N017f7e7c6aea485f9cc5ad50d69431cb
2 N3a4d212f7931405892495ad54ccc2377
3 N45e29d422efd4e6180063760777238cc
4 N5293a7b9759a4538b72b7f03d6931d93
5 N56a72e47ef574371a5dd7094f01331bb
6 N6136dbd1eb27450f88957d400ca1f029
7 N6fd4d2708ae54c5f853b32ce18aba185
8 N8119761e5fb94f51820d96fcf14f6a67
9 N842e916624af4c5fb852ff5cee8d7b55
10 N959a199ff0e94008ba7a7925fdfdc3f4
11 Na5557b99ae8043e1a4f0fda896b91e75
12 Na6e63508bf744e97b4f547df98131781
13 Nb107f5a1f524479c980d435aa16fbad1
14 Nb15c94beb757484196f4f19c8d594f4a
15 Ndbb5123a2fe74df8b540f57461132666
16 Ndd37cc6c7f464373a923812c22c638fd
17 Ne525315bc42a4a59b37ec324a153b2dd
18 Nf1883d2417d74061a95df41d977ce7b2
19 Nfd91d160563c4200a872ec5dceab5724
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N7a6563b4e7c84b2f80b93b7392b4b939
23 schema:citation sg:pub.10.1007/s00280-010-1377-y
24 sg:pub.10.1038/35048096
25 sg:pub.10.1038/leu.2010.15
26 sg:pub.10.1038/nrm1245
27 sg:pub.10.1054/bjoc.2000.1684
28 https://app.dimensions.ai/details/publication/pub.1075250639
29 https://app.dimensions.ai/details/publication/pub.1075266210
30 https://app.dimensions.ai/details/publication/pub.1077018133
31 https://doi.org/10.1002/ijc.1200
32 https://doi.org/10.1002/ijc.26324
33 https://doi.org/10.1002/path.1711690415
34 https://doi.org/10.1016/s0962-8924(00)01880-8
35 https://doi.org/10.1021/jm800984v
36 https://doi.org/10.1093/annonc/mdr451
37 https://doi.org/10.1093/emboj/17.11.3052
38 https://doi.org/10.1093/jnci/91.13.1160
39 https://doi.org/10.1093/jnci/92.3.205
40 https://doi.org/10.1093/jnci/94.17.1320
41 https://doi.org/10.1158/1078-0432.ccr-07-0431
42 https://doi.org/10.1158/1078-0432.ccr-07-5268
43 https://doi.org/10.1158/1535-7163.mct-10-0299
44 https://doi.org/10.1182/blood-2006-07-037671
45 https://doi.org/10.1200/jco.2008.26.15_suppl.2519
46 https://doi.org/10.3324/haematol.12148
47 https://doi.org/10.4161/cc.8.12.8741
48 schema:datePublished 2013-12
49 schema:datePublishedReg 2013-12-01
50 schema:description PURPOSE: AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and pharmacodynamic properties of AT9283. PATIENTS AND METHODS: Patients with advanced, incurable solid tumors or non-Hodgkin's lymphoma received AT9283 as a continuous 24-hour infusion on days 1, 8 of a 21-day cycle. A 3 + 3 dose escalation design was used with a starting dose of 1.5 mg/m(2)/day. Pharmacokinetic samples were collected from all patients on cycle one, and pharmacodynamic samples were collected from 4 patients at the recommended phase II dose (RP2D). RESULTS: 35 patients were evaluable for toxicity and 32 were evaluable for response. AT9283 was well tolerated, with main toxicities being reversible dose-related fatigue, gastrointestinal disturbance, anemia, lymphocytopenia and neutropenia. The dose limiting toxicities were febrile neutropenia (two patients) and neutropenia with grade 3 infection (1 patient) at 47 mg/m(2)/day (established as the maximum tolerated dose). The RP2D was 40 mg/m(2)/day. Pharmacokinetic analyses showed AT9283 appeared to follow linear kinetics, with a mean elimination half-life of 8.2 h. Pharmacodynamic analyses showed no consistent or significant changes, but trends suggested evidence of AT9283 inhibition and anti-proliferative activity. One patient had partial response and four patients experienced RECIST stable disease (median 2.6 months). CONCLUSION: In this study, AT9283 was well tolerated. The RP2D is 40 mg/m(2)/day on days 1, 8 of a 21-day cycle. Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers.
51 schema:genre research_article
52 schema:inLanguage en
53 schema:isAccessibleForFree false
54 schema:isPartOf Nd671ffd93dbb4483a46d9acee679cee7
55 Nfd724ef35a62407db421bd9e945b3122
56 sg:journal.1094201
57 schema:name NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
58 schema:pagination 1522-1529
59 schema:productId N56953384de35436c8dbf5627326a0352
60 N5f53750bb2f24244902eaa1848816632
61 Nc471a1d14da649dfacd00ffc1e0c7ae1
62 Nef83897d21544a0fa46268c62f43404b
63 Nf6e313c85f0c42adb94f8433dde5e326
64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030261706
65 https://doi.org/10.1007/s10637-013-0018-9
66 schema:sdDatePublished 2019-04-10T18:20
67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
68 schema:sdPublisher N989b1b710fcd41f68a0279f33870ffc3
69 schema:url http://link.springer.com/10.1007%2Fs10637-013-0018-9
70 sgo:license sg:explorer/license/
71 sgo:sdDataset articles
72 rdf:type schema:ScholarlyArticle
73 N017f7e7c6aea485f9cc5ad50d69431cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Female
75 rdf:type schema:DefinedTerm
76 N268ea80b60ed44ef9a1966054bfafd0f schema:name Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, 501 Smyth Rd, K1H 8L6, Ottawa, ON, Canada
77 rdf:type schema:Organization
78 N2957bfcfe9b041babce764f32139be11 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
79 schema:familyName Capier
80 schema:givenName C. A.
81 rdf:type schema:Person
82 N321d50fc3be44d83acbc9d3163cbcff5 rdf:first N2957bfcfe9b041babce764f32139be11
83 rdf:rest Nde75a71ef5664d5ca1e194c7c97c6bff
84 N3a4d212f7931405892495ad54ccc2377 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Ki-67 Antigen
86 rdf:type schema:DefinedTerm
87 N45e29d422efd4e6180063760777238cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Skin
89 rdf:type schema:DefinedTerm
90 N5293a7b9759a4538b72b7f03d6931d93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Drug Administration Schedule
92 rdf:type schema:DefinedTerm
93 N56953384de35436c8dbf5627326a0352 schema:name readcube_id
94 schema:value 9029856cbb059630e633c78f2e4fc60afab3851146d17aa78dc1cb765afd2c47
95 rdf:type schema:PropertyValue
96 N56a72e47ef574371a5dd7094f01331bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Aged, 80 and over
98 rdf:type schema:DefinedTerm
99 N5da3a6dac93c406e8d212b1c231f949b rdf:first sg:person.01327242410.25
100 rdf:rest rdf:nil
101 N5f53750bb2f24244902eaa1848816632 schema:name nlm_unique_id
102 schema:value 8309330
103 rdf:type schema:PropertyValue
104 N604a170a50ed477e9fd270dee51c2143 rdf:first sg:person.01133244421.43
105 rdf:rest N5da3a6dac93c406e8d212b1c231f949b
106 N6136dbd1eb27450f88957d400ca1f029 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Infusions, Intravenous
108 rdf:type schema:DefinedTerm
109 N6fd4d2708ae54c5f853b32ce18aba185 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Tumor Suppressor Protein p53
111 rdf:type schema:DefinedTerm
112 N71e32e5d46dc4054a3a5a2130408e6cb schema:name Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, 501 Smyth Rd, K1H 8L6, Ottawa, ON, Canada
113 rdf:type schema:Organization
114 N7a6563b4e7c84b2f80b93b7392b4b939 rdf:first sg:person.01005512156.68
115 rdf:rest Naa728394201b47f98f87d3f485ee9ada
116 N8119761e5fb94f51820d96fcf14f6a67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Histones
118 rdf:type schema:DefinedTerm
119 N816be24ae8514b4392969169b7ef3d83 rdf:first sg:person.0602472015.93
120 rdf:rest Nd0e22abcbc53459c803a7afefe459d40
121 N842e916624af4c5fb852ff5cee8d7b55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Humans
123 rdf:type schema:DefinedTerm
124 N959a199ff0e94008ba7a7925fdfdc3f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Adult
126 rdf:type schema:DefinedTerm
127 N989b1b710fcd41f68a0279f33870ffc3 schema:name Springer Nature - SN SciGraph project
128 rdf:type schema:Organization
129 Na5557b99ae8043e1a4f0fda896b91e75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Aged
131 rdf:type schema:DefinedTerm
132 Na6e63508bf744e97b4f547df98131781 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Proliferating Cell Nuclear Antigen
134 rdf:type schema:DefinedTerm
135 Naa728394201b47f98f87d3f485ee9ada rdf:first sg:person.01173252503.80
136 rdf:rest Nbb706aedd47b4e17a11352a9e494bf40
137 Nb107f5a1f524479c980d435aa16fbad1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Urea
139 rdf:type schema:DefinedTerm
140 Nb15c94beb757484196f4f19c8d594f4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Middle Aged
142 rdf:type schema:DefinedTerm
143 Nbb706aedd47b4e17a11352a9e494bf40 rdf:first sg:person.01142252161.65
144 rdf:rest N816be24ae8514b4392969169b7ef3d83
145 Nc471a1d14da649dfacd00ffc1e0c7ae1 schema:name dimensions_id
146 schema:value pub.1030261706
147 rdf:type schema:PropertyValue
148 Nd0e22abcbc53459c803a7afefe459d40 rdf:first sg:person.0725434730.09
149 rdf:rest N321d50fc3be44d83acbc9d3163cbcff5
150 Nd671ffd93dbb4483a46d9acee679cee7 schema:issueNumber 6
151 rdf:type schema:PublicationIssue
152 Ndbb5123a2fe74df8b540f57461132666 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Male
154 rdf:type schema:DefinedTerm
155 Ndd37cc6c7f464373a923812c22c638fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Antineoplastic Agents
157 rdf:type schema:DefinedTerm
158 Nde75a71ef5664d5ca1e194c7c97c6bff rdf:first sg:person.0754450325.91
159 rdf:rest N604a170a50ed477e9fd270dee51c2143
160 Ne525315bc42a4a59b37ec324a153b2dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Neoplasms
162 rdf:type schema:DefinedTerm
163 Ned94944a95cf454e8b42a155d965ee8e schema:name Astex Pharmaceuticals, Cambridge, UK
164 rdf:type schema:Organization
165 Nef83897d21544a0fa46268c62f43404b schema:name pubmed_id
166 schema:value 24072436
167 rdf:type schema:PropertyValue
168 Nf1883d2417d74061a95df41d977ce7b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Benzimidazoles
170 rdf:type schema:DefinedTerm
171 Nf6e313c85f0c42adb94f8433dde5e326 schema:name doi
172 schema:value 10.1007/s10637-013-0018-9
173 rdf:type schema:PropertyValue
174 Nfd724ef35a62407db421bd9e945b3122 schema:volumeNumber 31
175 rdf:type schema:PublicationVolume
176 Nfd91d160563c4200a872ec5dceab5724 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Protein Kinase Inhibitors
178 rdf:type schema:DefinedTerm
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
183 schema:name Oncology and Carcinogenesis
184 rdf:type schema:DefinedTerm
185 sg:journal.1094201 schema:issn 0167-6997
186 1573-0646
187 schema:name Investigational New Drugs
188 rdf:type schema:Periodical
189 sg:person.01005512156.68 schema:affiliation N71e32e5d46dc4054a3a5a2130408e6cb
190 schema:familyName Dent
191 schema:givenName S. F.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005512156.68
193 rdf:type schema:Person
194 sg:person.01133244421.43 schema:affiliation Ned94944a95cf454e8b42a155d965ee8e
195 schema:familyName Lyons
196 schema:givenName J. F.
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133244421.43
198 rdf:type schema:Person
199 sg:person.01142252161.65 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
200 schema:familyName Chi
201 schema:givenName K. N.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
203 rdf:type schema:Person
204 sg:person.01173252503.80 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
205 schema:familyName Gelmon
206 schema:givenName K. A.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80
208 rdf:type schema:Person
209 sg:person.01327242410.25 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
210 schema:familyName Seymour
211 schema:givenName L.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327242410.25
213 rdf:type schema:Person
214 sg:person.0602472015.93 schema:affiliation N268ea80b60ed44ef9a1966054bfafd0f
215 schema:familyName Jonker
216 schema:givenName D. J.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602472015.93
218 rdf:type schema:Person
219 sg:person.0725434730.09 schema:affiliation https://www.grid.ac/institutes/grid.410356.5
220 schema:familyName Wainman
221 schema:givenName N.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725434730.09
223 rdf:type schema:Person
224 sg:person.0754450325.91 schema:affiliation https://www.grid.ac/institutes/grid.415224.4
225 schema:familyName Chen
226 schema:givenName E. X.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754450325.91
228 rdf:type schema:Person
229 sg:pub.10.1007/s00280-010-1377-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1003176121
230 https://doi.org/10.1007/s00280-010-1377-y
231 rdf:type schema:CreativeWork
232 sg:pub.10.1038/35048096 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051541099
233 https://doi.org/10.1038/35048096
234 rdf:type schema:CreativeWork
235 sg:pub.10.1038/leu.2010.15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007310794
236 https://doi.org/10.1038/leu.2010.15
237 rdf:type schema:CreativeWork
238 sg:pub.10.1038/nrm1245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049953107
239 https://doi.org/10.1038/nrm1245
240 rdf:type schema:CreativeWork
241 sg:pub.10.1054/bjoc.2000.1684 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037558742
242 https://doi.org/10.1054/bjoc.2000.1684
243 rdf:type schema:CreativeWork
244 https://app.dimensions.ai/details/publication/pub.1075250639 schema:CreativeWork
245 https://app.dimensions.ai/details/publication/pub.1075266210 schema:CreativeWork
246 https://app.dimensions.ai/details/publication/pub.1077018133 schema:CreativeWork
247 https://doi.org/10.1002/ijc.1200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031753113
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1002/ijc.26324 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035093358
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1002/path.1711690415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009072534
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1016/s0962-8924(00)01880-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005800453
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1021/jm800984v schema:sameAs https://app.dimensions.ai/details/publication/pub.1055955939
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1093/annonc/mdr451 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041877696
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1093/emboj/17.11.3052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022175488
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1093/jnci/91.13.1160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006611610
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1093/jnci/94.17.1320 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009989679
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1158/1078-0432.ccr-07-0431 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011939272
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1158/1078-0432.ccr-07-5268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016270721
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1158/1535-7163.mct-10-0299 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020215440
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1182/blood-2006-07-037671 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035758193
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1200/jco.2008.26.15_suppl.2519 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079371368
276 rdf:type schema:CreativeWork
277 https://doi.org/10.3324/haematol.12148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036865215
278 rdf:type schema:CreativeWork
279 https://doi.org/10.4161/cc.8.12.8741 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072300058
280 rdf:type schema:CreativeWork
281 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
282 schema:name BC Cancer Agency - Vancouver Cancer Centre, Vancouver, BC, Canada
283 Division of Medical Oncology, BC Cancer Agency - Vancouver Cancer Centre, Vancouver, BC, Canada
284 rdf:type schema:Organization
285 https://www.grid.ac/institutes/grid.410356.5 schema:alternateName Queen's University
286 schema:name NCIC Clinical Trials Group, Cancer Research Institute, Kingston, ON, Canada
287 rdf:type schema:Organization
288 https://www.grid.ac/institutes/grid.415224.4 schema:alternateName Princess Margaret Cancer Centre
289 schema:name University Health Network-Princess Margaret Hospital, Oncology, Toronto, ON, Canada
290 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...